Tofacitinib is an orally available JAK3 inhibitor (IC50 = 1 nM), exhibiting 20- and 100-fold less potency against JAK2 and JAK1. Tofacitinib induces G1 cell cycle arrest and inhibits tumor growth in Epstein-Barr virus-associated T and natural killer cell lymphoma cells. It is approved for the treatment of rheumatoid arthritis (RA).
Products > Drug Discovery > Inhibitor | Products > Drug Discovery > Inhibitor | Inflammation / Immunology | JAK
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.
日本语
한국어
Français
Deutsch
España
Türkiye